Theophylline sodium glycinate

Cat. No.:	HY-107909
CAS No.:	8000-10-0
Molecular Formula:	$C_9H_{13}N_5NaO_4^+$
Molecular Weight:	278.22
Target:	Adenosine Receptor; HDAC; Apoptosis; Interleukin Related; TNF Receptor
Pathway:	GPCR/G Protein; Cell Cycle/DNA Damage; Epigenetics; Apoptosis; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Theophylline (1,3-Dimethylxanthine) sodium glycinate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline sodium glycinate inhibits PDE3 activity to relax airway smooth muscle. Theophylline sodium glycinate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline sodium glycinate induces apoptosis. Theophylline sodium glycinate can be used for asthma and chronic obstructive pulmonary disease (COPD) research[1][2][3][4][5].

In Vitro

Theophylline sodium glycinate (1-1000 μM) inhibits cAMP hydrolysis by PDE in homogenates of bronchial tissue to relax human bronchus and pulmonary arteries[1].

Theophylline sodium glycinate (10 μg/mL; 24 h) induces apoptosis through a reduction in the antiapoptotic protein Bcl-2 in eosinophils[2].

Theophylline sodium glycinate (0-500 μM; 2 h) inhibits NF-κB activation, I kappa B alpha (I-κBα) degradation and decreases the level of IL-6 in a concentration-dependent manner[3].

Theophylline sodium glycinate (0-1000 μM; 30 min; A549 cells) induces histone deacetylase activity to decrease inflammatory gene expression[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[3]

Cell Line:	A549 cells
Concentration:	0, 20, 100 and 500 μM
Incubation Time:	2 hours
Result:	Decreased the expression of NF-κB p65 and I-κBα degradation in a dose-dependent manner.

In Vivo

Theophylline sodium glycinate (100 mg/kg; i.p.; daily, for 9 d) has anti-inflammatory activity in mice and increases IL-6 and IL-10 levels and inhibits TNF-α and NO in male Swiss mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Swiss mice[1]

Dosage:	100 mg/kg
Administration:	Intraperitoneal injection; daily; for 9 days
Result:	Increased IL-6 and IL-10 levels and inhibited TNF-α and NO.

CUSTOMER VALIDATION

- Pharmacol Res Perspect. 2020 Apr;8(2):e00575.
- Eur J Drug Metab Pharmacokinet. 2022 Jun 22.
- Research Square Preprint. 2020 Oct.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Rabe KF, et, al. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J. 1995 Apr;8(4):637-42.

[2]. Németh ZH, et, al. Amrinone and theophylline differentially regulate cytokine and nitric oxide production in endotoxemic mice. Shock. 1997 May;7(5):371-5.

[3]. Ito K, et, al, Adcock IM, Barnes PJ. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8921-6.

[4]. Barnes PJ. Theophylline. Am J Respir Crit Care Med. 2013 Oct 15;188(8):901-6.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA